查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1617124

內視鏡逆行性造影設備市場至2030年的預測：按產品類型、技術、應用、最終用戶和地區的全球分析

Endoscopic Retrograde Cholangiopancreatography Devices Market Forecasts to 2030 - Global Analysis by Product, Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2024年全球內視鏡逆行性造影（ERCP）設備市場規模為 16.286億美元，預測期內年複合成長率為 8.3%，預計到2030年將達到 26億美元。

內視鏡逆行性造影（ERCP）設備是用於診斷和治療膽胰管的專用醫療設備。 ERCP結合內視鏡和透視檢查來觀察和治療惡性、狹窄和膽管結石。在手術過程中，將軟式內視鏡經由口腔插入十二指腸。然後使用切片檢查鉗、擴張器、支架和導管等專用儀器清除堵塞物、放置支架並收集組織樣本。 ERCP 機器對於胰臟和膽道疾病的診斷和治療非常重要，因為它們提供了高精度和微創的解決方案。

根據美國國家癌症資料庫，美國68.5%的胰臟癌診斷是在 65 歲及以上的人群中進行的。

膽道和胰臟疾病的盛行率增加

膽結石、膽道狹窄和胰臟炎等膽胰疾病的盛行率不斷增加，推動了對內視鏡逆行性造影（ERCP）設備的需求。這些疾病的有效治療取決於準確的診斷和治療，而ERCP手術非常重要。病例數的不斷增加，尤其是老年人病例數量的增加，推動 ERCP 設備的使用並推動市場擴張。隨著微創治療和 ERCP 的早期檢測改善患者的治療效果，市場進一步擴大。

ERCP 手術和設備高成本

ERCP 手術和設備的高成本阻礙了市場擴張，特別是在醫療資源有限的低收入和中等收入國家。對專家的需求、高昂的設備成本和手術成本可能會阻礙醫院和診所實施 ERCP 技術。此外，儘管 ERCP 設備具有治療功效，但阻礙其廣泛採用的是保險範圍和支付問題，這可能會限制患者接受這些尖端手術。

微創手術的進展

微創手術的進步透過提高治療準確性和安全性對 ERCP 設備市場產生重大影響。改進的內視鏡影像、更緊湊和靈活的設備以及複雜的切片檢查儀器都是技術創新的例子，這些技術創新可以實現更好的治療結果和診斷，同時縮短患者的康復時間。隨著患者選擇侵入性較小的替代標準手術，ERCP 機器的需求不斷增加。這些發展也增加了治療選擇、減少問題並簡化程序，支持市場成長。

併發症的風險

胰臟炎、出血、感染疾病等併發症的風險阻礙了ERCP設備的廣泛使用。特別是在高風險情況下，這些風險可能會阻礙患者選擇 ERCP，也可能會阻礙醫療保健提供者對其提供支援。此外，並非所有設施都能夠安全地執行如此先進的程序，這需要高素質的專業人員來緩解困難，增加成本並可能阻礙市場擴張。

COVID-19 的影響：

COVID-19 的爆發嚴重影響了內視鏡逆行性造影（ERCP）設備市場，由於醫療保健系統的壓力，導致選擇性手術的延誤和取消。因此，對 ERCP 設備的需求有所下降。然而，隨著醫療保健系統的復甦，微創診斷和治療技術，尤其是胃腸道和膽道疾病的微創診斷和治療技術越來越受到關注，市場預計將復甦。

切片檢查鉗領域預計將成為預測期內最大的市場

由於胰臟和膽道疾病對準確診斷技術的需求不斷增加，切片檢查鉗細分市場預計將在預測期內成為最大的市場。在 ERCP 過程中，切片檢查鉗可以採集組織樣本，有助於早期診斷狹窄、癌症和其他異常情況。由於胃腸道疾病的增加和微創手術的改進，切片檢查鉗的使用日益增加。提高安全性和準確性是另外兩個支持市場擴張的設計因素。

預計擴張器細分在預測期內的年複合成長率最高。

由於膽道疾病的盛行率不斷上升、微創手術技術的進步以及對精確有效手術的需求不斷成長，預計擴張器領域在預測期內將出現最高的年複合成長率。為了確保內視鏡順利通過，需要使用擴張器來擴張胰管或膽管的狹窄處。由於一次性用品、人體工學設計和增強的安全功能（方便擴張器的使用）等技術進步，ERCP 設備市場日益擴大。

佔有率最大的地區

由於胰臟炎、膽管癌和膽結石等膽道疾病的盛行率不斷增加，預計北美將在預測期內佔據最大的市場佔有率。 ERCP 設備的技術發展提高了治療準確性和患者治療效果，包括增強的影像系統和微創治療。此外，該地區較高的醫療保健支出、完善的醫療保健基礎設施以及尖端醫療技術利用率的不斷提高，支持了對 ERCP 設備不斷成長的需求，推動了市場擴張。

年複合成長率最高的地區：

由於醫療基礎設施的增加、膽道和胰臟疾病發病率的上升以及人口老化的加劇，預計亞太地區在預測期內的年複合成長率最高。 ERCP 技術的進步，包括診斷影像和微創技術的改進，提高診斷和治療能力。此外，擴大該地區的醫療服務範圍、增加醫療旅遊以及先進醫療設備的採用推動對 ERCP 設備的需求，刺激亞太地區的市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之1：

  • 公司簡介
    • 其他市場公司的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依產品

  • 內視鏡治療裝置
  • 內視鏡
  • 影像裝置
  • 括約肌切開術
  • 支架
  • 球囊導管
  • 切片檢查鉗
  • 導管導引線
  • 擴張器
  • 其他產品

第6章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依類型

  • 傳統ERCP
  • 單操作ERCP
  • 腹腔鏡ERCP
  • 超音波（EUS）引導下的ERCP
  • 其他類型

第7章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依技術分類

  • 先進的成像系統
  • 機器人輔助ERCP
  • 與人工智慧和機器學習整合
  • 其他技術

第8章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依應用分類

  • 診斷性ERCP
    • 膽管癌
    • 胰臟炎
    • 膽結石
    • 膽管狹窄
  • 治療性ERCP
    • 石材開採
    • 支架置入
    • 括約肌切開術
    • 狹窄擴張
    • 排放受感染的膽汁
  • 其他用途

第9章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依最終使用者分類

  • 醫院
  • 專科診所
  • 門診手術中心
  • 研究/學術機構
  • 其他最終用戶

第10章 全球經內視鏡逆行性膽胰管攝影術（ERCP）設備市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東、非洲

第11章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • AMBU, Inc.
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Group
  • FUJIFILM Holdings Corporation
  • Hobbs Medical, Inc.
  • HOYA Group
  • Karl Storz SE & Co. KG
  • Medi-Globe GmbH
  • Medline Industries, Inc.
  • Medtronic PLC
  • Olympus Corporation
  • Streis PLC
  • Stryker Corporation
  • Taewoong Medical Co., Ltd.
  • Telemed System, Inc.
Product Code: SMRC28002

According to Stratistics MRC, the Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market is accounted for $1628.6 million in 2024 and is expected to reach $2627.7 million by 2030 growing at a CAGR of 8.3% during the forecast period. Endoscopic Retrograde Cholangiopancreatography (ERCP) devices are specialist medical equipment used to perform diagnostic and therapeutic treatments on the bile and pancreatic channels. Endoscopy and fluoroscopy are combined in ERCP to view and treat malignancies, strictures, and bile duct stones. A flexible endoscope is inserted through the mouth into the duodenum during the surgery. There, specialized tools such as biopsy forceps, dilators, stents, and catheters are used to clear blockages, put stents, or take tissue samples. Because they provide highly accurate, minimally invasive solutions, ERCP devices are essential for the diagnosis and treatment of pancreatic and biliary disorders.

According to the National Cancer Database, 68.5% of pancreatic cancer diagnoses in the United States are made in people over 65 years old.

Market Dynamics:

Driver:

Increasing Prevalence of Biliary and Pancreatic Disorders

The growing prevalence of biliary and pancreatic illnesses, such as gallstones, bile duct strictures, and pancreatitis, pushes up demand for Endoscopic Retrograde Cholangiopancreatography (ERCP) equipment. Effective management of these disorders depends on precise diagnosis and treatment, which makes ERCP procedures crucial. The growing number of instances, especially in older populations, encourages the use of ERCP devices and propels market expansion. The market is further expanded by ERCP's minimally invasive treatments and early identification, which enhance patient outcomes.

Restraint:

High Cost of ERCP Procedures and Devices

The high cost of ERCP procedures and equipment stifles market expansion, especially in low- and middle-income countries with restricted healthcare resources. The necessity for specialist personnel, high equipment costs, and procedural expenses may discourage hospitals and clinics from implementing ERCP technology. Further impeding the broad adoption of ERCP devices despite their therapeutic benefits are insurance coverage and payment issues, which can limit patient access to these cutting-edge procedures.

Opportunity:

Advancements in Minimally Invasive Procedures

Advances in minimally invasive techniques have a substantial impact on the ERCP device market by improving treatment precision and safety. Improved endoscopic imaging, more compact and flexible devices, and sophisticated biopsy instruments are examples of innovations that allow for better therapy results and diagnostics while shortening recuperation periods for patients. ERCP devices are becoming more and more in demand as patients choose less intrusive alternatives to standard surgery. These developments also increase treatment options, decrease problems, and streamline procedures, which support the market's growth.

Threat:

Risk of Complications

The risk of complications, such as pancreatitis, bleeding, or infections, prevents widespread use of ERCP devices. Particularly in high-risk situations, these possible hazards can discourage patients from choosing ERCP procedures and medical professionals from endorsing them. Additionally, as not all facilities may be prepared to carry out such sophisticated procedures safely; the requirement for highly qualified experts to reduce difficulties can raise costs and hinder market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Endoscopic Retrograde Cholangiopancreatography (ERCP) devices market, leading to delays and cancellations of elective procedures due to healthcare system strain. This resulted in reduced demand for ERCP devices. However, as healthcare systems recover, the market is expected to rebound with increased focus on minimally invasive diagnostic and therapeutic procedures, particularly for gastrointestinal and biliary disorders.

The biopsy forceps segment is expected to be the largest during the forecast period

The biopsy forceps segment is expected to be the largest during the forecast period because there is a growing need for precise diagnostic techniques for pancreatic and biliary disorders. During ERCP, biopsy forceps make it possible to take tissue samples, which aids in the early diagnosis of strictures, cancer, and other anomalies. The use of biopsy forceps is increased by the growing incidence of gastrointestinal disorders and improvements in minimally invasive procedures. Improved safety and accuracy are two more design elements that support market expansion.

The dilators segment is expected to have the highest CAGR during the forecast period

The dilators segment is expected to have the highest CAGR during the forecast period owing to the rising prevalence of biliary problems, advances in minimally invasive surgical techniques, and the increased desire for precise and effective procedures. In order to ensure smoother endoscope transit, dilators are necessary to dilate the strictures in the pancreatic and bile ducts. The market for ERCP devices is expanding as a result of technological advancements such disposable, ergonomic designs, and enhanced safety features that encourage the use of dilators.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because biliary tract conditions like pancreatitis, cholangiocarcinoma, and gallstones are becoming more common. Treatment accuracy and patient outcomes are being improved by technological developments in ERCP devices, including as enhanced imaging systems and minimally invasive treatments. Furthermore, the region's high healthcare spending, well-established healthcare infrastructure, and rising use of cutting-edge medical technology all support the rising demand for ERCP devices, which in turn propels the market's expansion.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period due to increasing healthcare infrastructure, rising incidences of biliary and pancreatic diseases, and a growing aging population. Advancements in ERCP technologies, such as improved imaging and minimally invasive techniques, are enhancing diagnostic and therapeutic capabilities. Additionally, the region's expanding healthcare access, rising medical tourism and adoption of advanced medical devices are boosting the demand for ERCP devices, fueling market growth in Asia Pacific.

Key players in the market

Some of the key players in Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market include AMBU, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, CONMED Corporation, Cook Group, FUJIFILM Holdings Corporation, Hobbs Medical, Inc., HOYA Group, Karl Storz SE & Co. KG, Medi-Globe GmbH, Medline Industries, Inc., Medtronic PLC, Olympus Corporation, Streis PLC, Stryker Corporation, Taewoong Medical Co., Ltd. and Telemed System, Inc.

Key Developments:

In September 2024, Medtronic expanded AiBLE spine surgery ecosystem with new technologies and Siemens Healthineers partnership.

In April 2024, Medtronic plc announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO(TM), the latest generation software for the GI Genius(TM) intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

In December 2023, Medtronic plc announced that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, to offer continued innovation and scalable healthcare advancements for patients and caregivers globally.

Products Covered:

  • Endotherapy Devices
  • Endoscopes
  • Imaging Devices
  • Sphincterotomes
  • Stents
  • Balloon Catheters
  • Biopsy Forceps
  • Guidewires
  • Dilators
  • Other Products

Types Covered:

  • Conventional ERCP
  • Single-Operator ERCP
  • Laparoscopic ERCP
  • Endoscopic Ultrasound (EUS)-Guided ERCP
  • Other Types

Technologies Covered:

  • Advanced Imaging Systems
  • Robotic-Assisted ERCP
  • Integration with AI and Machine Learning
  • Other Technologies

Applications Covered:

  • Diagnostic ERCP
  • Therapeutic ERCP
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research and Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Product

  • 5.1 Introduction
  • 5.2 Endotherapy Devices
  • 5.3 Endoscopes
  • 5.4 Imaging Devices
  • 5.5 Sphincterotomes
  • 5.6 Stents
  • 5.7 Balloon Catheters
  • 5.8 Biopsy Forceps
  • 5.9 Guidewires
  • 5.10 Dilators
  • 5.11 Other Products

6 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Type

  • 6.1 Introduction
  • 6.2 Conventional ERCP
  • 6.3 Single-Operator ERCP
  • 6.4 Laparoscopic ERCP
  • 6.5 Endoscopic Ultrasound (EUS)-Guided ERCP
  • 6.6 Other Types

7 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Technology

  • 7.1 Introduction
  • 7.2 Advanced Imaging Systems
  • 7.3 Robotic-Assisted ERCP
  • 7.4 Integration with AI and Machine Learning
  • 7.5 Other Technologies

8 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostic ERCP
    • 8.2.1 Cholangiocarcinoma
    • 8.2.2 Pancreatitis
    • 8.2.3 Gallstones
    • 8.2.4 Biliary Strictures
  • 8.3 Therapeutic ERCP
    • 8.3.1 Stone Extraction
    • 8.3.2 Stent Placement
    • 8.3.3 Sphincterotomy
    • 8.3.4 Dilation of Strictures
    • 8.3.5 Drainage of Infected Bile
  • 8.4 Other Applications

9 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Research and Academic Institutions
  • 9.6 Other End Users

10 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AMBU, Inc.
  • 12.2 B. Braun Melsungen AG
  • 12.3 Boston Scientific Corporation
  • 12.4 CONMED Corporation
  • 12.5 Cook Group
  • 12.6 FUJIFILM Holdings Corporation
  • 12.7 Hobbs Medical, Inc.
  • 12.8 HOYA Group
  • 12.9 Karl Storz SE & Co. KG
  • 12.10 Medi-Globe GmbH
  • 12.11 Medline Industries, Inc.
  • 12.12 Medtronic PLC
  • 12.13 Olympus Corporation
  • 12.14 Streis PLC
  • 12.15 Stryker Corporation
  • 12.16 Taewoong Medical Co., Ltd.
  • 12.17 Telemed System, Inc.

List of Tables

  • Table 1 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endotherapy Devices (2022-2030) ($MN)
  • Table 4 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endoscopes (2022-2030) ($MN)
  • Table 5 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Imaging Devices (2022-2030) ($MN)
  • Table 6 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Sphincterotomes (2022-2030) ($MN)
  • Table 7 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stents (2022-2030) ($MN)
  • Table 8 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Balloon Catheters (2022-2030) ($MN)
  • Table 9 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Biopsy Forceps (2022-2030) ($MN)
  • Table 10 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Guidewires (2022-2030) ($MN)
  • Table 11 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Dilators (2022-2030) ($MN)
  • Table 12 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 13 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Type (2022-2030) ($MN)
  • Table 14 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Conventional ERCP (2022-2030) ($MN)
  • Table 15 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Single-Operator ERCP (2022-2030) ($MN)
  • Table 16 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Laparoscopic ERCP (2022-2030) ($MN)
  • Table 17 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endoscopic Ultrasound (EUS)-Guided ERCP (2022-2030) ($MN)
  • Table 18 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 19 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Technology (2022-2030) ($MN)
  • Table 20 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Advanced Imaging Systems (2022-2030) ($MN)
  • Table 21 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Robotic-Assisted ERCP (2022-2030) ($MN)
  • Table 22 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Integration with AI and Machine Learning (2022-2030) ($MN)
  • Table 23 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 24 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Application (2022-2030) ($MN)
  • Table 25 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Diagnostic ERCP (2022-2030) ($MN)
  • Table 26 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Cholangiocarcinoma (2022-2030) ($MN)
  • Table 27 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Pancreatitis (2022-2030) ($MN)
  • Table 28 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Gallstones (2022-2030) ($MN)
  • Table 29 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Biliary Strictures (2022-2030) ($MN)
  • Table 30 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Therapeutic ERCP (2022-2030) ($MN)
  • Table 31 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stone Extraction (2022-2030) ($MN)
  • Table 32 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stent Placement (2022-2030) ($MN)
  • Table 33 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Sphincterotomy (2022-2030) ($MN)
  • Table 34 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Dilation of Strictures (2022-2030) ($MN)
  • Table 35 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Drainage of Infected Bile (2022-2030) ($MN)
  • Table 36 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 37 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By End User (2022-2030) ($MN)
  • Table 38 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 39 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 40 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 41 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Research and Academic Institutions (2022-2030) ($MN)
  • Table 42 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.